Immunologic mechanisms of seasonal influenza vaccination administered by microneedle patch from a randomized phase I trial

微针贴片接种季节性流感疫苗的免疫机制随机 I 期临床试验

阅读:7
作者:Nadine G Rouphael, Lilin Lai, Sonia Tandon, Michele Paine McCullough, Yunchuan Kong, Sarah Kabbani, Muktha S Natrajan, Yongxian Xu, Yerun Zhu, Dongli Wang, Jesse O'Shea, Amy Sherman, Tianwei Yu, Sebastien Henry, Devin McAllister, Daniel Stadlbauer, Surender Khurana, Hana Golding, Florian Krammer, Ma

Abstract

In a phase 1 randomized, single-center clinical trial, inactivated influenza virus vaccine delivered through dissolvable microneedle patches (MNPs) was found to be safe and immunogenic. Here, we compare the humoral and cellular immunologic responses in a subset of participants receiving influenza vaccination by MNP to the intramuscular (IM) route of administration. We collected serum, plasma, and peripheral blood mononuclear cells in 22 participants up to 180 days post-vaccination. Hemagglutination inhibition (HAI) titers and antibody avidity were similar after MNP and IM vaccination, even though MNP vaccination used a lower antigen dose. MNPs generated higher neuraminidase inhibition (NAI) titers for all three influenza virus vaccine strains tested and triggered a larger percentage of circulating T follicular helper cells (CD4 + CXCR5 + CXCR3 + ICOS + PD-1+) compared to the IM route. Our study indicates that inactivated influenza virus vaccination by MNP produces humoral and cellular immune response that are similar or greater than IM vaccination.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。